Insys Therapeutics, Inc. (INSY) announced that the FDA granted the Fast Track designation to its CBD formulation for the treatment of Dravet’s syndrome. INSY’s new, DEA-inspected facility will allow the company to manufacture mass quantities of CBD for its research and commercial plans.
“Coupled with our candidate’s orphan drug designation in Dravet syndrome, Fast Track designation represents significant additional support of our goal of addressing the significant medical need of children suffering from this rare and catastrophic treatment-resistant form of pediatric epilepsy,” said Michael L. Babich, President and Chief Executive Officer of Insys. “Rapid advancement of our pharmaceutical CBD program is a key priority for Insys, and we are pleased to be initiating clinical trials with this program in 2015. These include a Phase I/pharmacokinetic study in epilepsy patients and a Phase III clinical trial in patients suffering from Dravet syndrome and Lennox Gastaut syndrome, a second rare form of pediatric epilepsy for which our pharmaceutical CBD has received orphan drug designation.”
Technical420 is favorable on this news because it will speed up the FDA process (which is a very slow process). The commencement of Phase I and III trials will be a catalyst for the stock and it should keep market sentiment in positive territory. This news may lead to investment firms further increasing its price target on INSY, which would also be a catalyst for the stock. Investors need to understand that INSY is not like the typical marijuana stock. INSY is a pharmaceutical company which is also focused on the cannabis sector. The company is a competitor to GWPH, but they aren’t a pure-play cannabis company like GWPH. All of GWPH’s revenue is generated off of cannabis derived products, which is not the case for INSY.
In a league of their own
INSY and GWPH are in a league of their own when compared to marijuana stocks. These two companies possess three attributes that other marijuana stocks can only dream of having right now. These attributes include:
They trade on a national exchange, the Nasdaq
They have institutional investors
They have Wall Street coverage
INSY and GWPH cannot be treated like your typical marijuana stock because they are not marijuana stocks. These companies are not in their developmental stage, both of them were founded more than 15 years ago. INSY and GWPH are led by a management team that has a proven track record and act in the best interests of shareholders.
Which company is the better investment?
Technical420 is favorable on both companies and they both possess qualities which makes them an attractive long term investment. Here are the differences between the two companies.
GWPH is U.K based, INSY is U.S based
GWPH pipeline of pharmaceutical products is deeper (more extensive) than INSY.
INSY generates a majority of its revenue off of Subsys which is not a cannabis-based drug. The company is focused on producing drugs from synthetic marijuana. GWPH generates a majority of its revenue from Sativex, which is the first pharmaceutical drug derived from cannabis.
If you want to learn more about GW Pharmaceuticals (GWPH) and INSYS Therapeutics (INSY), check out Technical420’s in-depth research reports on the two companies by clicking the links below.